September 25–28, 2024, Amsterdam

European Academy of Dermatology and Venereology (EADV)

September 07–10, 2022, Hybrid Meeting

European Academy of Dermatology and Venereology (EADV)

Poster icon

Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study

M. Maurer, A.M. Giménez-Arnau, V. Jain, A. Reich, C-E. Ortmann, P. Walsh,
S. Haemmerle
Poster
Poster icon

Remibrutinib, an oral, highly selective BTKi in development for CSU: Analysis of safety data from the completed Phase 2 studies in inflammatory immune-mediated diseases

A.M. Giménez-Arnau, T. Chitnis, M. Williams, L. Airas, S. Saini, M. Hide, G. Sussman, J. Nakahara, R. Bermel, T. Dörner, B. Loop, V. DeLasHeras, R. Willi, B.C. Kieseier,
S. Haemmerle, R. Siegel, B. Cenni, H. Wiendl, M. Maurer, X. Montalban, A. Zharkov
Oral presentation
Poster icon

Remibrutinib treatment improves itch, sleep and activity in chronic spontaneous urticaria patients: Phase 2b study results

A.M. Giménez-Arnau, C. Hsu, R. Snyder, L. Clore, V. Jain, K. Lheritier, P. Walsh,
S. Haemmerle, M. Wells, I. Nikolaev, M. Maurer
Poster
Poster icon

Remibrutinib (LOU064) treatment decreases disease activity in patients with chronic spontaneous urticaria: Post hoc analysis from the Phase 2b study

A.M. Giménez-Arnau, M. Maurer, R. Snyder, C-E. Ortmann, B. Suryawanshi,
I. Nikolaev, M. Kuruvilla, S. Haemmerle
Oral presentation
Poster icon

Remibrutinib provides fast and clinically important improvement of CSU disease activity: Post-hoc analysis from the Phase 2b study

M. Maurer, A.M. Giménez-Arnau, J. Jacobs, S. Savic, C-E. Ortmann, B. Suryawanshi, I. Nikolaev, M. Wells, S. Haemmerle
Oral presentation
Poster icon

Remibrutinib improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Results from a Phase 2b study

M. Maurer, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh,
I. Nikolaev, A.M. Giménez-Arnau
Poster
Poster icon

Urticaria Voices: The use of patient-reported outcome measures for monitoring chronic spontaneous urticaria in clinical practice

J.A. Bernstein, P. Laires, M-M. Balp, P. Saraswat, T. Raftery, J. McCarthy, M. Dricu,
T.A. Winders, K. Weller
Poster
Poster icon

Urticaria Voices: Patients’ perspective on the negative impact of chronic spontaneous urticaria on their lives as well as their treatment goals

K. Weller, P. Laires, M-M. Balp, T. Raftery, P. Saraswat, J. McCarthy, M. Dricu,
T.A. Winders, J.A. Bernstein
Poster
Poster icon

Urticaria Voices: Opportunity for greater shared treatment decision-making by leveraging the existing high-quality relationship between patients and physicians

T.A. Winders, P. Laires, M-M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Dricu,
J.A. Bernstein, K. Weller
Poster
Poster icon

Remission and relapse profiles in chronic urticaria using real-world data​

M-M. Balp, I. Pivneva, A. Danyliv, K. Chen, T. Cornwall , J. Signorovitch, D. Patil,
R.K. Kohli, T. Severin, W. Soong, A.M. Marsland
Poster
Poster icon

Burden of angioedema in patients with chronic spontaneous urticaria in EU5 and US

M-M. Balp, K. Krupsky, L. Balkaran. Bridget, S. Gupta, C. Lienhard, D. Patil, R.K. Kohli, F. Tétart, T. El-Shanawany, J. Reed
Poster
Poster icon

Burden of chronic spontaneous urticaria relative to psoriasis and atopic dermatitis in Japan

M-M. Balp, M. Hide, A. Uda, F. Maki, R.K. Kohli, S. Gupta, K. Krupsky, B.L. Balkaran
Poster
Poster icon

Characterization of chronic spontaneous urticaria among patients in EU5, US and Japan

M-M. Balp, K. Krupsky, B.L. Balkaran, S. Gupta, C. Lienhard, D. Patil, R.K. Kohli,
A. Uda, F. Maki, F. Tétart, T. El-Shanawany, J. Reed, M. Hide
Poster
Poster icon

Patient-reported symptom burden in chronic inducible urticaria: Post hoc analysis of baseline data from a Phase 3 clinical trial

D. Whalley, M-M. Balp, S. Yarr, M. Porter, A. Barve
Poster
Poster icon

Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, M. Metz, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini, E. Şavk, G. Sussman, R. Szalewski, I.W. Herniczek, H. Windom, B. Yang, S. Haemmerle, K. Lheritier, Paula G.P. Machado, E-D. Martzloff, N. Seko, P. Wang, A. Zharkov, M. Maurer
Oral Presentation
Poster icon

Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the Phase 3 REMIX-1 and
REMIX-2 studies

M. Metz, S. Saini, F. Berard, J. Reed, M. Maurer, S. Altrichter, C-Y. Chu, B. Suryawanshi, C-E. Ortmann, N. Chapman-Rothe, S. Haemmerle, J. Kern
e-Poster
Poster icon

CSU disease activity band shift after long-term treatment with remibrutinib in the Phase 3 REMIX-1 & REMIX-2 studies

M. Metz, A. M. Giménez-Arnau, P. Staubach, M.F. Puga, K. Kulthanan, X-H. Gao, K. Lheritier, C-E. Ortmann, N. Chapman-Rothe, S. Haemmerle, A. Fukunaga, M. Hide
e-Poster
Poster icon

Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies

J. Reed, M. Metz, R. Saini, R. Szalewski, M. Lebwohl, M. Maurer, G. Sussman, S. Haemmerle, N. Seko, P. Wang, C. Field, M. J. Palumbo
e-Poster
Poster icon

Impact of chronic spontaneous urticaria on health-related quality of life domains: Country-specific data from patients participating in the Urticaria Voices study

T. A. Winders, J.A. Bernstein, J. McCarthy, P. Saraswat, N. Chapman-Rothe, T. Raftery, K. Weller
e-Poster
Poster icon

Physicians' perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

J. A. Bernstein, T. A. Winders, J. McCarthy, P. Saraswat, N. Chapman-Rothe, T. Raftery, K. Weller
e-Poster
Poster icon

Utility scores in chronic spontaneous urticaria: A systematic literature review and statistical analysis

R. Kohli, E. Hawe, S. Harold, E. Simou, A. Chrysos, P. Orfanos
e-Poster
Novartis logo
Cookie Settings
© Copyright 2024 Novartis Pharma AG